Approved Equity Investment for Establishing a New Manufacturing Facility in Angola

Net loss reportedNegative operating cash flowDebt to equity above the thresholdResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+9.2%Reaction day

₹2.82

prior close

₹3.04

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.2%+8.0% vs market

Civil Construction peers, median of 85sector+1.2%+8.0% vs sector

On the reaction day the stock moved 8.0 pts more than Nifty Microcap 250 and 8.0 pts more than its Civil Construction peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.7

10m

-0.3

15m

-1.0

30m

-1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+9.2+1.2+8.0+1.2+8.0

Next day

+11.3+0.1+11.2-0.3+11.7

+6.4+0.9+5.5-0.1+6.5

+7.1+0.8+6.3-0.6+7.7

+6.7+1.4+5.3-0.3+7.1

+8.2+2.0+6.1+0.2+8.0

+6.7+2.3+4.5+1.0+5.8

15d

+7.4+5.2+2.3+2.2+5.3

+4.6+1.6+3.0-0.5+5.1

+1.8+7.7-5.9+1.7+0.1

-2.5+4.0-6.5-3.2+0.7

UpDownMarket · Nifty Microcap 250Sector · Civil Construction peers, median of 85Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vivanta Industries' board approved acquiring a 35% equity stake in Angola-based Angav Indústria Farmacêutica S.A. as part of a partnership to sell pharmaceutical products internationally. The company also approved the sale of ~6.25 Bigha of freehold land in Sanand, Ahmedabad (no impact on operations), and appointed new Internal and Secretarial Auditors, while the Company Secretary Ms. Vinita Keswani resigned effective May 6, 2025. On the financial side, consolidated FY25 revenue surged to Rs. 10,980.34 lakhs (vs Rs. 3,723.86 lakhs in FY24, ~195% growth), largely driven by its newly acquired subsidiary Trinity Ganesh Pvt Ltd. However, the company swung to a consolidated loss of Rs. 132.22 lakhs (vs Rs. 92.50 lakh profit in FY24), with cost of materials consumed jumping to Rs. 8,570.44 lakhs. Standalone revenue declined to Rs. 2,285.31 lakhs with a loss of Rs. 119.58 lakhs. Trade receivables and payables both ballooned sharply, borrowings rose to Rs. 2,186 lakhs, and operating cash flow remained negative at Rs. (538.29) lakhs.

Likely market impact

The Angola entry signals international pharma ambitions but execution risk is high given the company has just turned loss-making with negative operating cash flows and rising debt. Shareholders should watch for due diligence outcomes, the impact of the land sale on liquidity, and whether the subsidiary-driven revenue growth can be converted into profitability in FY26.